首页 > 最新文献

Bioimpacts最新文献

英文 中文
STAT signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis.
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-11 eCollection Date: 2025-01-01 DOI: 10.34172/bi.30030
Sepideh Sohrabi, Shiva Alipour, Zahra Ghahramanipour, Javad Masoumi, Behzad Baradaran

Introduction: Signal transducer and activator of transcriptions (STATs) factors as critical proteins in cell signaling regulate diverse biological processes such as differentiation and proliferation of cells. STATs have been shown to play distinct roles in modulating immune responses mediated by innate and adaptive immune cell subsets due to their significant roles in cytokine signaling.

Methods: In the current study, we review recent studies on the contribution of individual STAT proteins to cytokine signaling, development, and activity of diverse immune cells that constitute the whole immune system and help its performance against endogenous or exogenous agents with a particular focus on meaningful STAT factor in each of innate and adaptive immune cells' subsets to clarify their function in favor of the tumor or against it.

Results: Dysregulation of signaling pathways in the immune cells is associated with various immune disorders, such as the inability of immune system cells in the effective destruction of cancerous cells. Increase of knowledge about these pathways' functions is essential to understand how they can be effectively targeted to eliminate tumors.

Conclusion: The majority of immune cells use the Jak/STAT signaling pathway, which is one of the most important signaling pathways with a role in induction of proper immune responses. Since each of the STAT factors has a specific role in diverse immune cells' subsets, appropriate targeting of them can be a promising strategy for patients who suffer from immune system disorders; specifically it can be beneficial as an approach for cancer immunotherapy.

{"title":"STAT signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis.","authors":"Sepideh Sohrabi, Shiva Alipour, Zahra Ghahramanipour, Javad Masoumi, Behzad Baradaran","doi":"10.34172/bi.30030","DOIUrl":"10.34172/bi.30030","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Signal transducer and activator of transcriptions (STATs) factors as critical proteins in cell signaling regulate diverse biological processes such as differentiation and proliferation of cells. STATs have been shown to play distinct roles in modulating immune responses mediated by innate and adaptive immune cell subsets due to their significant roles in cytokine signaling.</p><p><strong>Methods: </strong>In the current study, we review recent studies on the contribution of individual STAT proteins to cytokine signaling, development, and activity of diverse immune cells that constitute the whole immune system and help its performance against endogenous or exogenous agents with a particular focus on meaningful STAT factor in each of innate and adaptive immune cells' subsets to clarify their function in favor of the tumor or against it.</p><p><strong>Results: </strong>Dysregulation of signaling pathways in the immune cells is associated with various immune disorders, such as the inability of immune system cells in the effective destruction of cancerous cells. Increase of knowledge about these pathways' functions is essential to understand how they can be effectively targeted to eliminate tumors.</p><p><strong>Conclusion: </strong>The majority of immune cells use the Jak/STAT signaling pathway, which is one of the most important signaling pathways with a role in induction of proper immune responses. Since each of the STAT factors has a specific role in diverse immune cells' subsets, appropriate targeting of them can be a promising strategy for patients who suffer from immune system disorders; specifically it can be beneficial as an approach for cancer immunotherapy.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30030"},"PeriodicalIF":2.2,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A promising breakthrough in pancreatic cancer research: The potential of spheroids as 3D models.
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-06 eCollection Date: 2025-01-01 DOI: 10.34172/bi.30241
Nazanin Jamshidi, Negar Jamshidi, Amir Modarresi Chahardehi, Elahe Shams, Vahid Chaleshi

Pancreatic ductal adenocarcinoma (PDAC) stands as the fourth leading cause of cancer-related deaths, primarily attributable to its resistance to chemotherapy, resulting in a nearly universal fatality rate. Despite the promise exhibited by numerous drugs in preclinical studies, their subsequent failure in clinical trials underscores the inherent limitations of conventional two-dimensional cell culture models commonly employed in early drug screening endeavors. The inadequacies of two-dimensional (2D) models prompted the exploration of three-dimensional (3D) culture systems, which more faithfully recapitulate the native tumor microenvironment. These 3D systems have distinct advantages over 2D models in morphology, proliferation, drug response, and protein expression. Among these 3D platforms, tumor organoids and spheroids, generated through different methodologies, have emerged as next-generation models that closely mirror aspects of pancreatic tumor biology. This comprehensive review scrutinizes pancreatic cancer spheroids' techniques, tissue sources, and applications, offering a nuanced analysis of their advantages and limitations. By comparing these distinct 3D culture systems, researchers gain valuable insights to inform the selection of optimal model designs aligned with their specific experimental objectives. The utilization of these advanced models holds significant promise for enhancing the clinical relevance of both in vitro and in vivo cancer research, thereby contributing to the development of improved therapeutics against pancreatic cancer.

{"title":"A promising breakthrough in pancreatic cancer research: The potential of spheroids as 3D models.","authors":"Nazanin Jamshidi, Negar Jamshidi, Amir Modarresi Chahardehi, Elahe Shams, Vahid Chaleshi","doi":"10.34172/bi.30241","DOIUrl":"10.34172/bi.30241","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) stands as the fourth leading cause of cancer-related deaths, primarily attributable to its resistance to chemotherapy, resulting in a nearly universal fatality rate. Despite the promise exhibited by numerous drugs in preclinical studies, their subsequent failure in clinical trials underscores the inherent limitations of conventional two-dimensional cell culture models commonly employed in early drug screening endeavors. The inadequacies of two-dimensional (2D) models prompted the exploration of three-dimensional (3D) culture systems, which more faithfully recapitulate the native tumor microenvironment. These 3D systems have distinct advantages over 2D models in morphology, proliferation, drug response, and protein expression. Among these 3D platforms, tumor organoids and spheroids, generated through different methodologies, have emerged as next-generation models that closely mirror aspects of pancreatic tumor biology. This comprehensive review scrutinizes pancreatic cancer spheroids' techniques, tissue sources, and applications, offering a nuanced analysis of their advantages and limitations. By comparing these distinct 3D culture systems, researchers gain valuable insights to inform the selection of optimal model designs aligned with their specific experimental objectives. The utilization of these advanced models holds significant promise for enhancing the clinical relevance of both <i>in vitro</i> and <i>in vivo</i> cancer research, thereby contributing to the development of improved therapeutics against pancreatic cancer.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30241"},"PeriodicalIF":2.2,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SBFI-26 enhances apoptosis in docetaxel-treated triple-negative breast cancer cells by increasing ROS levels.
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-30 eCollection Date: 2025-01-01 DOI: 10.34172/bi.30137
Gang He, Mei Liu, Tang Cong Chen, Li Fen Huang, You Qiang Ke

Introduction: Fatty acid binding protein 5 (FABP5) exhibits heightened expression levels in triple-negative breast cancer. The inhibitor of FABP5, Stony Brook fatty acid-binding protein inhibitor 26 (SBFI-26), has demonstrated the capacity to suppress cell proliferation, migration, and invasion. This study delves into the functional mechanism and impact of combining SBFI-26 with docetaxel in treating MDA-MB-231 cells of triple-negative breast cancer.

Methods: Various concentrations of docetaxel and SBFI-26 were chosen for individual or combined treatments. The effects of SBFI-26, docetaxel, or their combination on cell cycle arrest and apoptosis were assessed using flow cytometry. Western blotting was utilised to detect the expression of apoptosis-related proteins, namely cysteinyl aspartate-specific proteases 3 (Caspase3), B cell leukemia/lymphoma 2 (Bcl-2), and Bcl-2 associated X (Bax), while intracellular reactive oxygen species (ROS) levels were determined using a fluorescence spectrophotometer.

Results: The IC50 values for SBFI-26 and docetaxel in inhibiting MDA-MB-231 cells were determined to be 106.1 μM and 86.14 nM, respectively. Significantly, the combination treatment augmented the proportion of G1 phase (apoptotic) cells by 3.67-fold compared to the control group (P < 0.0001). Furthermore, the apoptosis rate in the combination group was 2.59-fold higher than that in the docetaxel group (P < 0.0001) and demonstrated a significant increase of 1.82-fold compared with the SBFI-26 group (P < 0.001). Analyses revealed a decrease in the protein expression of Bcl-2, while Bax and Caspase3 exhibited an increase in the combination group for MDA-MB-231 cells. Moreover, the combined treatment group demonstrated a 2.97-fold increase (P < 0.0001) in ROS fluorescence intensity compared to the control group, a noteworthy 1.39-fold increase (P < 0.01) compared to the SBFI-26 treatment group, and a substantial 1.70-fold increase (P < 0.0001) compared to the docetaxel treatment group.

Conclusion: These findings suggest that the co-administration of SBFI-26 with docetaxel effectively enhances apoptosis in triple-negative breast cancer MDA-MB-231 cells by elevating intracellular ROS levels.

{"title":"SBFI-26 enhances apoptosis in docetaxel-treated triple-negative breast cancer cells by increasing ROS levels.","authors":"Gang He, Mei Liu, Tang Cong Chen, Li Fen Huang, You Qiang Ke","doi":"10.34172/bi.30137","DOIUrl":"10.34172/bi.30137","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Fatty acid binding protein 5 (FABP5) exhibits heightened expression levels in triple-negative breast cancer. The inhibitor of FABP5, Stony Brook fatty acid-binding protein inhibitor 26 (SBFI-26), has demonstrated the capacity to suppress cell proliferation, migration, and invasion. This study delves into the functional mechanism and impact of combining SBFI-26 with docetaxel in treating MDA-MB-231 cells of triple-negative breast cancer.</p><p><strong>Methods: </strong>Various concentrations of docetaxel and SBFI-26 were chosen for individual or combined treatments. The effects of SBFI-26, docetaxel, or their combination on cell cycle arrest and apoptosis were assessed using flow cytometry. Western blotting was utilised to detect the expression of apoptosis-related proteins, namely cysteinyl aspartate-specific proteases 3 (Caspase3), B cell leukemia/lymphoma 2 (Bcl-2), and Bcl-2 associated X (Bax), while intracellular reactive oxygen species (ROS) levels were determined using a fluorescence spectrophotometer.</p><p><strong>Results: </strong>The IC50 values for SBFI-26 and docetaxel in inhibiting MDA-MB-231 cells were determined to be 106.1 μM and 86.14 nM, respectively. Significantly, the combination treatment augmented the proportion of G1 phase (apoptotic) cells by 3.67-fold compared to the control group (<i>P</i> < 0.0001). Furthermore, the apoptosis rate in the combination group was 2.59-fold higher than that in the docetaxel group (<i>P</i> < 0.0001) and demonstrated a significant increase of 1.82-fold compared with the SBFI-26 group (<i>P</i> < 0.001). Analyses revealed a decrease in the protein expression of Bcl-2, while Bax and Caspase3 exhibited an increase in the combination group for MDA-MB-231 cells. Moreover, the combined treatment group demonstrated a 2.97-fold increase (<i>P</i> < 0.0001) in ROS fluorescence intensity compared to the control group, a noteworthy 1.39-fold increase (<i>P</i> < 0.01) compared to the SBFI-26 treatment group, and a substantial 1.70-fold increase (<i>P</i> < 0.0001) compared to the docetaxel treatment group.</p><p><strong>Conclusion: </strong>These findings suggest that the co-administration of SBFI-26 with docetaxel effectively enhances apoptosis in triple-negative breast cancer MDA-MB-231 cells by elevating intracellular ROS levels.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30137"},"PeriodicalIF":2.2,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of mesenchymal stem cell sheet with poly-caprolactone nanofibrous mat and Gelfoam increased osteogenesis capacity in rat calvarial defect.
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-28 eCollection Date: 2025-01-01 DOI: 10.34172/bi.30006
Behnaz Banimohamad-Shotorbani, Reza Rahbarghazi, Seyedhosein Jarolmasjed, Ahmad Mehdipour, Hajar Shafaei

Introduction: To date, different strategies have been used for co-transplantation of cell-loaded biomaterials for bone tissue regeneration. This study aimed to investigate the osteogenic properties of adipose-derived-mesenchymal stem cell (AD-MSC) sheets combined with nanofibrous poly-caprolactone (PCL) mat and Gelfoam in rats with calvarial bone defect.

Methods: Calvarial critical-size defects were induced in male rats. Animals were classified into Control, Gelfoam, Gelfoam/PCL nanofiber, Gelfoam/AD-MSC sheet, and Gelfoam/PCL nanofiber/AD-MSC sheet groups. After 3 months, rats were sacrificed and the regeneration rate was evaluated.

Results: Almost all groups showed bone regeneration properties, but the volume of newly formed bone was higher in groups that received Gelfoam/AD-MSC and Gelfoam/PCL nanofiber/AD-MSC sheets (P < 0.05). The application of Gelfoam/PCL nanofiber/AD-MSC sheets not only increased bone thickness, bone volume/total bone volume (BV/TV) ratio, strong Hounsfield Unit (HU), but also led to the formation of ossified connective tissue with wrinkled patterns.

Conclusion: The current study indicated that the Gelfoam/PCL nanofiber/AD-MSC sheet provides a suitable platform for effective osteogenesis in calvarial bone defects.

{"title":"Combination of mesenchymal stem cell sheet with poly-caprolactone nanofibrous mat and Gelfoam increased osteogenesis capacity in rat calvarial defect.","authors":"Behnaz Banimohamad-Shotorbani, Reza Rahbarghazi, Seyedhosein Jarolmasjed, Ahmad Mehdipour, Hajar Shafaei","doi":"10.34172/bi.30006","DOIUrl":"10.34172/bi.30006","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>To date, different strategies have been used for co-transplantation of cell-loaded biomaterials for bone tissue regeneration. This study aimed to investigate the osteogenic properties of adipose-derived-mesenchymal stem cell (AD-MSC) sheets combined with nanofibrous poly-caprolactone (PCL) mat and Gelfoam in rats with calvarial bone defect.</p><p><strong>Methods: </strong>Calvarial critical-size defects were induced in male rats. Animals were classified into Control, Gelfoam, Gelfoam/PCL nanofiber, Gelfoam/AD-MSC sheet, and Gelfoam/PCL nanofiber/AD-MSC sheet groups. After 3 months, rats were sacrificed and the regeneration rate was evaluated.</p><p><strong>Results: </strong>Almost all groups showed bone regeneration properties, but the volume of newly formed bone was higher in groups that received Gelfoam/AD-MSC and Gelfoam/PCL nanofiber/AD-MSC sheets (<i>P </i>< 0.05). The application of Gelfoam/PCL nanofiber/AD-MSC sheets not only increased bone thickness, bone volume/total bone volume (BV/TV) ratio, strong Hounsfield Unit (HU), but also led to the formation of ossified connective tissue with wrinkled patterns.</p><p><strong>Conclusion: </strong>The current study indicated that the Gelfoam/PCL nanofiber/AD-MSC sheet provides a suitable platform for effective osteogenesis in calvarial bone defects.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30006"},"PeriodicalIF":2.2,"publicationDate":"2024-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-28 eCollection Date: 2025-01-01 DOI: 10.34172/bi.30071
Seyedeh Maryam Mortazavi, Seyyed Ali Mohammadi Vadoud, Hamid Reza Moghimi

Introduction: Peptides are promising and attractive anti-wrinkle active ingredients, amongst which glycyl-histidyl-lysine peptide (GHK) is one of the most broadly promoted peptide for topical application. This simple sequence of amino acid residues not only has the capability of tissue regeneration and the enhancement of collagen and glycosaminoglycans synthesis but also is able to increase nerve outgrowth and angiogenesis. Consequently, GHK has several properties, from wound healing to prevention/reduction wrinkles. GHK-Cu and Pal-GHK are metal complex and palmitoylated derivatives of GHK, respectively. Although GHK-Cu and Pal-GHK are widely used in anti-wrinkle products available on the cosmetic market, the published information on their skin permeability, effectiveness, physicochemical properties and so on is insufficient.

Methods: This review aims to highlight whether GHK is sufficiently effective on wrinkle prevention/reduction. Apart from the effectiveness, another question that is tried to be answered is whether skin permeability of GHK allows it to act as an anti-wrinkle peptide at its site of action? Skin permeation enhancement methods employed so far are also reviewed.

Results: Based on cellular studies, undoubtedly, GHK can be considered as an anti-wrinkle ingredient. Although GHK-Cu and Pal-GHK have been of interest as effective peptides to be incorporated in the anti-wrinkle products, there is a surprising absence of clinical studies using them. Metal complexation and chemical modification with a hydrophobic moiety increase permeability of this peptide. Besides, cell penetrating peptides seem promising to increase skin permeation of GHK and its derivatives. Skin pretreatment with microneedles also has the potential to be further studied for permeation enhancement of such peptides. As peptide ingredients, their formulation may encounter some challenges, mainly due to their hydrophilic (high aqueous solubility and low partition coefficient) and unstable nature.

Conclusion: Although GHK-Cu and Pal-GHK are effective and relatively skin permeable, their permeability could be successfully increased using permeation enhancement methodologies.

{"title":"Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.","authors":"Seyedeh Maryam Mortazavi, Seyyed Ali Mohammadi Vadoud, Hamid Reza Moghimi","doi":"10.34172/bi.30071","DOIUrl":"10.34172/bi.30071","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Peptides are promising and attractive anti-wrinkle active ingredients, amongst which glycyl-histidyl-lysine peptide (GHK) is one of the most broadly promoted peptide for topical application. This simple sequence of amino acid residues not only has the capability of tissue regeneration and the enhancement of collagen and glycosaminoglycans synthesis but also is able to increase nerve outgrowth and angiogenesis. Consequently, GHK has several properties, from wound healing to prevention/reduction wrinkles. GHK-Cu and Pal-GHK are metal complex and palmitoylated derivatives of GHK, respectively. Although GHK-Cu and Pal-GHK are widely used in anti-wrinkle products available on the cosmetic market, the published information on their skin permeability, effectiveness, physicochemical properties and so on is insufficient.</p><p><strong>Methods: </strong>This review aims to highlight whether GHK is sufficiently effective on wrinkle prevention/reduction. Apart from the effectiveness, another question that is tried to be answered is whether skin permeability of GHK allows it to act as an anti-wrinkle peptide at its site of action? Skin permeation enhancement methods employed so far are also reviewed.</p><p><strong>Results: </strong>Based on cellular studies, undoubtedly, GHK can be considered as an anti-wrinkle ingredient. Although GHK-Cu and Pal-GHK have been of interest as effective peptides to be incorporated in the anti-wrinkle products, there is a surprising absence of clinical studies using them. Metal complexation and chemical modification with a hydrophobic moiety increase permeability of this peptide. Besides, cell penetrating peptides seem promising to increase skin permeation of GHK and its derivatives. Skin pretreatment with microneedles also has the potential to be further studied for permeation enhancement of such peptides. As peptide ingredients, their formulation may encounter some challenges, mainly due to their hydrophilic (high aqueous solubility and low partition coefficient) and unstable nature.</p><p><strong>Conclusion: </strong>Although GHK-Cu and Pal-GHK are effective and relatively skin permeable, their permeability could be successfully increased using permeation enhancement methodologies.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30071"},"PeriodicalIF":2.2,"publicationDate":"2024-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mosaic vaccine design targeting mutational spike protein of SAR-SCoV-2: An immunoinformatics approach. 针对严重急性呼吸系统综合征冠状病毒2型突变刺突蛋白的嵌合疫苗设计:一种免疫信息学方法
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-22 eCollection Date: 2025-01-01 DOI: 10.34172/bi.2023.26443
Ysrafil Ysrafil, Arlan K Imran, Prisca Syafriani Wicita, Vyani Kamba, Fihrina Mohamad, Ismail Ismail, Ayyub Harly Nurung, Noviyanty Indjar Gama, Sari Eka Pratiwi, Indwiani Astuti, Firzan Nainu, Talha Bin Emran

Introduction: Presently, the development of effective vaccines against SARS-CoV-2 is absolutely necessary, especially regarding the emergence of new variants that cause increasing morbidity and fatalities.

Methods: In the present study we designed a mosaic vaccine targeting the mutational spike protein of COVID-19 using a bioinformatics approach. Various immunoinformatics tools were utilized to provide the highest potential for a mosaic vaccine that could activate immune responses against COVID-19.

Results: The evaluation of the constructed vaccine revealed that it is antigenic and immunogenic as well as nonallergenic. The physicochemical properties also show promising characteristics, including being highly stable and hydrophilic. As expected, the vaccine shows strong interactions with several important receptors including angiotensin-converting enzyme 2 (ACE2), Toll-like receptor 3 (TLR3) and TLR8 by the lowest energy level, docking score and binding free energy. The vaccine binds to receptors via certain amino acids using various types of binding including salt bridges, hydrogen bonds, and other means. As shown in computationally derived models, the interactions promote activation of the immune response by eliciting the release of various cytokines, antibodies, memory B and T cells, as well as increasing of natural killer cell and dendrite cell counts.

Conclusion: Therefore, the novel designed mosaic vaccine could be considered as a potential vaccine candidate for immediate production to stem the continuing and tragic effects of the COVID-19 pandemic. However, several advanced experimental studies should be conducted to ensure and verify the effectivity and safety against SARS‑CoV‑2 in vivo.

引言:目前,开发针对严重急性呼吸系统综合征冠状病毒2型的有效疫苗是绝对必要的,特别是在出现导致死亡人数增加的新变种方面。方法:在本研究中,我们使用生物信息学方法设计了一种针对2019冠状病毒病(新冠肺炎)突变刺突蛋白的马赛克疫苗。利用各种免疫信息学工具为马赛克疫苗提供了最高潜力,该疫苗可以激活针对新冠肺炎的免疫反应。结果:构建的疫苗具有抗原性、免疫原性和非致敏性。理化性质也显示出有前景的特性,包括高度稳定和亲水性。正如预期的那样,该疫苗以最低的能量水平、对接得分和结合自由能与包括血管紧张素转换酶(ACE)2、Toll样受体(TLR)3和TLR8在内的几种重要受体表现出强烈的相互作用。疫苗通过某些氨基酸与受体结合,使用各种类型的结合,包括盐桥、氢键和其他方式。如计算推导的模型所示,相互作用通过引发各种细胞因子、抗体、记忆B和T细胞的释放,以及自然杀伤细胞和树突细胞计数的增加,促进免疫反应的激活。结论:因此,新设计的马赛克疫苗可以被视为立即生产的潜在候选疫苗,以阻止新冠肺炎大流行的持续和悲剧性影响。然而,应进行几项先进的实验研究,以确保和验证体内对抗严重急性呼吸系统综合征冠状病毒2型的有效性和安全性。
{"title":"Mosaic vaccine design targeting mutational spike protein of SAR-SCoV-2: An immunoinformatics approach.","authors":"Ysrafil Ysrafil, Arlan K Imran, Prisca Syafriani Wicita, Vyani Kamba, Fihrina Mohamad, Ismail Ismail, Ayyub Harly Nurung, Noviyanty Indjar Gama, Sari Eka Pratiwi, Indwiani Astuti, Firzan Nainu, Talha Bin Emran","doi":"10.34172/bi.2023.26443","DOIUrl":"10.34172/bi.2023.26443","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Presently, the development of effective vaccines against SARS-CoV-2 is absolutely necessary, especially regarding the emergence of new variants that cause increasing morbidity and fatalities.</p><p><strong>Methods: </strong>In the present study we designed a mosaic vaccine targeting the mutational spike protein of COVID-19 using a bioinformatics approach. Various immunoinformatics tools were utilized to provide the highest potential for a mosaic vaccine that could activate immune responses against COVID-19.</p><p><strong>Results: </strong>The evaluation of the constructed vaccine revealed that it is antigenic and immunogenic as well as nonallergenic. The physicochemical properties also show promising characteristics, including being highly stable and hydrophilic. As expected, the vaccine shows strong interactions with several important receptors including angiotensin-converting enzyme 2 (ACE2), Toll-like receptor 3 (TLR3) and TLR8 by the lowest energy level, docking score and binding free energy. The vaccine binds to receptors via certain amino acids using various types of binding including salt bridges, hydrogen bonds, and other means. As shown in computationally derived models, the interactions promote activation of the immune response by eliciting the release of various cytokines, antibodies, memory B and T cells, as well as increasing of natural killer cell and dendrite cell counts.</p><p><strong>Conclusion: </strong>Therefore, the novel designed mosaic vaccine could be considered as a potential vaccine candidate for immediate production to stem the continuing and tragic effects of the COVID-19 pandemic. However, several advanced experimental studies should be conducted to ensure and verify the effectivity and safety against SARS‑CoV‑2 <i>in vivo</i>.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":" ","pages":"26443"},"PeriodicalIF":2.2,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49334743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oil-in-water nanoemulsions for glaucoma treatment: An insight into the latest trends.
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-15 eCollection Date: 2025-01-01 DOI: 10.34172/bi.2024.30224
Ankita Kishore, Alok Kumar Mahor, Niraj Kumar Singh, Prem Prakash Singh, Priyanka Rathore, Kuldeep Kumar Bansal

Glaucoma is a serious eye disease characterized by elevated intraocular pressure, which can ultimately lead to blindness, making it the second leading cause of blindness worldwide, following cataracts. The condition is associated with various risk factors and primarily affects the optic nerve. To treat glaucoma, a range of approaches, both traditional and innovative, have been employed. Recently, there has been a significant focus on nanoemulsions as a promising avenue for treatment. This review underscores the advantages of using oil-in-water nanoemulsions for ocular drug delivery, showcasing their superiority in terms of enhanced bioavailability and stability compared with other dispersion systems. This review also delves into the limitations inherent in traditional drug formulations, elucidates the mechanisms governing drug release, explores the pivotal role of surfactants, and examines the landscape of granted patents in this domain. By addressing these critical aspects, the review offers invaluable insights into the treatment of glaucoma, shedding light on innovative approaches that hold great promise in the fight against this debilitating eye condition. During our search, it was noticed that despite the existence of commendable research in the field of ocular nanoemulsions, particularly in the context of glaucoma along with granted patents, the commercialized nanoemulsion formulations for glaucoma is not yet exist.

{"title":"Oil-in-water nanoemulsions for glaucoma treatment: An insight into the latest trends.","authors":"Ankita Kishore, Alok Kumar Mahor, Niraj Kumar Singh, Prem Prakash Singh, Priyanka Rathore, Kuldeep Kumar Bansal","doi":"10.34172/bi.2024.30224","DOIUrl":"10.34172/bi.2024.30224","url":null,"abstract":"<p><p>Glaucoma is a serious eye disease characterized by elevated intraocular pressure, which can ultimately lead to blindness, making it the second leading cause of blindness worldwide, following cataracts. The condition is associated with various risk factors and primarily affects the optic nerve. To treat glaucoma, a range of approaches, both traditional and innovative, have been employed. Recently, there has been a significant focus on nanoemulsions as a promising avenue for treatment. This review underscores the advantages of using oil-in-water nanoemulsions for ocular drug delivery, showcasing their superiority in terms of enhanced bioavailability and stability compared with other dispersion systems. This review also delves into the limitations inherent in traditional drug formulations, elucidates the mechanisms governing drug release, explores the pivotal role of surfactants, and examines the landscape of granted patents in this domain. By addressing these critical aspects, the review offers invaluable insights into the treatment of glaucoma, shedding light on innovative approaches that hold great promise in the fight against this debilitating eye condition. During our search, it was noticed that despite the existence of commendable research in the field of ocular nanoemulsions, particularly in the context of glaucoma along with granted patents, the commercialized nanoemulsion formulations for glaucoma is not yet exist.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30224"},"PeriodicalIF":2.2,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
University rankings: Time to reconsider.
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-06 eCollection Date: 2025-01-01 DOI: 10.34172/bi.2024.30290
Khaled Moustafa

University rankings offer some benefits but also come with significant drawbacks. While they can encourage healthy competition, they often lead to unethical practices and prioritize short- term gains over long-term educational purposes. Relying on biased metrics like citations and journal impact factors is a major flaw, potentially misrepresenting the true value of scholarly work. The foremost focus of universities should be on educating proficient students, advancing dependable knowledge, and addressing societal needs. Annual rankings based on one year's criteria and output prove impractical, as research outcomes and educational impact require more time to materialize. It is crucial to consider abandoning or reevaluating ranking systems to prevent biased, financially-driven approaches from causing harm. An internal assessment, gauging satisfaction levels within the university community and the quality of education provided, could offer a more effective approach to ranking universities. Acknowledging the negative impact of journal rankings took decades. It is imperative to avoid subjecting educational systems to similarly detrimental effects from university rankings. The most effective method for ranking universities is through an internal system that takes into account the satisfaction levels of university community members regarding their work conditions and overall institution, as well as whether students are acquiring the education and skills they seek.

{"title":"University rankings: Time to reconsider.","authors":"Khaled Moustafa","doi":"10.34172/bi.2024.30290","DOIUrl":"10.34172/bi.2024.30290","url":null,"abstract":"<p><p>University rankings offer some benefits but also come with significant drawbacks. While they can encourage healthy competition, they often lead to unethical practices and prioritize short- term gains over long-term educational purposes. Relying on biased metrics like citations and journal impact factors is a major flaw, potentially misrepresenting the true value of scholarly work. The foremost focus of universities should be on educating proficient students, advancing dependable knowledge, and addressing societal needs. Annual rankings based on one year's criteria and output prove impractical, as research outcomes and educational impact require more time to materialize. It is crucial to consider abandoning or reevaluating ranking systems to prevent biased, financially-driven approaches from causing harm. An internal assessment, gauging satisfaction levels within the university community and the quality of education provided, could offer a more effective approach to ranking universities. Acknowledging the negative impact of journal rankings took decades. It is imperative to avoid subjecting educational systems to similarly detrimental effects from university rankings. The most effective method for ranking universities is through an internal system that takes into account the satisfaction levels of university community members regarding their work conditions and overall institution, as well as whether students are acquiring the education and skills they seek.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30290"},"PeriodicalIF":2.2,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of parenteral L-carnitine in hospitalized patients with moderate to severe COVID-19: A randomized double-blind clinical trial.
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-06 eCollection Date: 2025-01-01 DOI: 10.34172/bi.2024.30261
Farnaz Naeimzadeh, Armin Sadeghi, Seiedhadi Saghaleini, Parvin Sarbakhsh, Ata Mahmoodpoor, Afshin Gharekhani

Introduction: Pro-inflammatory responses have an important role in developing coronavirus disease 2019 (COVID-19). L-carnitine (LC) has been known to possess anti-inflammatory, anticoagulant, and antiviral effects. So, we aimed to evaluate the efficacy of LC in hospitalized patients with moderate-to-severe COVID-19.

Methods: This double-blind, placebo-controlled, randomized clinical trial was conducted on hospitalized patients with moderate to severe COVID-19. The patients were randomized (1:1) to receive LC (n = 50) at a dose of 20 mg/kg or matching placebo (n = 51) from normal saline once daily for 14 days or until hospitalization and standard care. The primary outcome was hospital mortality and disease severity according to the World Health Organization's clinical progression scale. We also assessed the free carnitine level at baseline and the end of the study. C-reactive protein (CRP), ferritin, D-dimer, lactate dehydrogenase (LDH), and improvement of respiratory conditions were chosen as secondary outcomes.

Results: From 104 patients who met the inclusion criteria, 101 individuals' data were analyzed. The LC group showed a significant reduction in LDH levels (P = 0.003), although CRP, ferritin, and D-dimer levels did not significantly differ from the placebo group. Also, no significant difference was observed in disease severity, oxygenation status, hospital mortality, or hospital stay between the two groups. Additionally, there was no increase in serum-free carnitine levels in the LC group (P > 0.05 for all).

Conclusion: The results of the current study did not support the superiority of LC over placebo in improving oxygenation, decreasing mortality, and hospital stay, as well as CRP, ferritin, and D-dimer in moderate to severe COVID-19 patients.

Trial registration: IRCT20170609034406N10; https://en.irct.ir/trial/60306.

{"title":"Effect of parenteral L-carnitine in hospitalized patients with moderate to severe COVID-19: A randomized double-blind clinical trial.","authors":"Farnaz Naeimzadeh, Armin Sadeghi, Seiedhadi Saghaleini, Parvin Sarbakhsh, Ata Mahmoodpoor, Afshin Gharekhani","doi":"10.34172/bi.2024.30261","DOIUrl":"10.34172/bi.2024.30261","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Pro-inflammatory responses have an important role in developing coronavirus disease 2019 (COVID-19). L-carnitine (LC) has been known to possess anti-inflammatory, anticoagulant, and antiviral effects. So, we aimed to evaluate the efficacy of LC in hospitalized patients with moderate-to-severe COVID-19.</p><p><strong>Methods: </strong>This double-blind, placebo-controlled, randomized clinical trial was conducted on hospitalized patients with moderate to severe COVID-19. The patients were randomized (1:1) to receive LC (n = 50) at a dose of 20 mg/kg or matching placebo (n = 51) from normal saline once daily for 14 days or until hospitalization and standard care. The primary outcome was hospital mortality and disease severity according to the World Health Organization's clinical progression scale. We also assessed the free carnitine level at baseline and the end of the study. C-reactive protein (CRP), ferritin, D-dimer, lactate dehydrogenase (LDH), and improvement of respiratory conditions were chosen as secondary outcomes.</p><p><strong>Results: </strong>From 104 patients who met the inclusion criteria, 101 individuals' data were analyzed. The LC group showed a significant reduction in LDH levels (<i>P</i> = 0.003), although CRP, ferritin, and D-dimer levels did not significantly differ from the placebo group. Also, no significant difference was observed in disease severity, oxygenation status, hospital mortality, or hospital stay between the two groups. Additionally, there was no increase in serum-free carnitine levels in the LC group (<i>P</i> > 0.05 for all).</p><p><strong>Conclusion: </strong>The results of the current study did not support the superiority of LC over placebo in improving oxygenation, decreasing mortality, and hospital stay, as well as CRP, ferritin, and D-dimer in moderate to severe COVID-19 patients.</p><p><strong>Trial registration: </strong>IRCT20170609034406N10; https://en.irct.ir/trial/60306.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30261"},"PeriodicalIF":2.2,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CRISPR-Cas9 in basic and translational aspects of cancer therapy. CRISPR-Cas9 在癌症治疗的基础和转化方面的应用。
IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-03-10 DOI: 10.34172/bi.2024.30087
Maryam Samareh Salavatipour, Zahra Poursalehi, Negin Hosseini Rouzbahani, Sohaib Mohammadyar, Mohammad Vasei

Introduction: The discovery of gene editing techniques has opened a new era within the field of biology and enabled scientists to manipulate nucleic acid molecules. CRISPR-Cas9 genome engineering has revolutionized this achievement by successful targeting the DNA molecule and editing its sequence. Since genomic changes are the basis of the birth and growth of many tumors, CRISPR-Cas9 method has been successfully applied to identify and manipulate the genes which are involved in initiating and driving some neoplastic processes.

Methods: By review of the existing literature on application of CRISPR-Cas9 in cancer, different databases, such as PubMed and Google Scholar, we started data collection for "CRISPR-Cas9", "Genome Editing", "Cancer", "Solid tumors", "Hematologic malignancy" "Immunotherapy", "Diagnosis", "Drug resistance" phrases. Clinicaltrials.gov, a resource that provides access to information on clinical trials, was also searched in this review.

Results: We have defined the basics of this technology and then mentioned some clinical and preclinical studies using this technology in the treatment of a variety of solid tumors as well as hematologic neoplasms. Finally, we described the progress made by this technology in boosting immune-mediated cell therapy in oncology, such as CAR-T cells, CAR-NK cells, and CAR-M cells.

Conclusion: CRISPR-Cas9 system revolutionized the therapeutic strategies in some solid malignant tumors and leukemia through targeting the key genes involved in the pathogenesis of these cancers.

引言基因编辑技术的发现开创了生物学领域的新纪元,使科学家能够操纵核酸分子。CRISPR-Cas9基因组工程成功锁定DNA分子并编辑其序列,从而彻底改变了这一成就。由于基因组变化是许多肿瘤诞生和生长的基础,CRISPR-Cas9 方法已被成功应用于识别和操纵参与启动和驱动某些肿瘤过程的基因:通过查阅有关 CRISPR-Cas9 在癌症中应用的现有文献、PubMed 和 Google Scholar 等不同数据库,我们开始收集 "CRISPR-Cas9"、"基因组编辑"、"癌症"、"实体瘤"、"血液恶性肿瘤"、"免疫疗法"、"诊断"、"耐药性 "等词组的数据。本综述还搜索了 Clinicaltrials.gov,这是一个提供临床试验信息的资源:结果:我们对这一技术的基本原理进行了定义,然后提到了利用这一技术治疗各种实体瘤和血液肿瘤的一些临床和临床前研究。最后,我们介绍了这项技术在促进肿瘤免疫细胞疗法(如 CAR-T 细胞、CAR-NK 细胞和 CAR-M 细胞)方面取得的进展:CRISPR-Cas9系统通过靶向参与癌症发病机制的关键基因,彻底改变了一些实体恶性肿瘤和白血病的治疗策略。
{"title":"CRISPR-Cas9 in basic and translational aspects of cancer therapy.","authors":"Maryam Samareh Salavatipour, Zahra Poursalehi, Negin Hosseini Rouzbahani, Sohaib Mohammadyar, Mohammad Vasei","doi":"10.34172/bi.2024.30087","DOIUrl":"10.34172/bi.2024.30087","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>The discovery of gene editing techniques has opened a new era within the field of biology and enabled scientists to manipulate nucleic acid molecules. CRISPR-Cas9 genome engineering has revolutionized this achievement by successful targeting the DNA molecule and editing its sequence. Since genomic changes are the basis of the birth and growth of many tumors, CRISPR-Cas9 method has been successfully applied to identify and manipulate the genes which are involved in initiating and driving some neoplastic processes.</p><p><strong>Methods: </strong>By review of the existing literature on application of CRISPR-Cas9 in cancer, different databases, such as PubMed and Google Scholar, we started data collection for \"CRISPR-Cas9\", \"Genome Editing\", \"Cancer\", \"Solid tumors\", \"Hematologic malignancy\" \"Immunotherapy\", \"Diagnosis\", \"Drug resistance\" phrases. Clinicaltrials.gov, a resource that provides access to information on clinical trials, was also searched in this review.</p><p><strong>Results: </strong>We have defined the basics of this technology and then mentioned some clinical and preclinical studies using this technology in the treatment of a variety of solid tumors as well as hematologic neoplasms. Finally, we described the progress made by this technology in boosting immune-mediated cell therapy in oncology, such as CAR-T cells, CAR-NK cells, and CAR-M cells.</p><p><strong>Conclusion: </strong>CRISPR-Cas9 system revolutionized the therapeutic strategies in some solid malignant tumors and leukemia through targeting the key genes involved in the pathogenesis of these cancers.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"14 6","pages":"30087"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Bioimpacts
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1